CGEN-15001T

CGEN-15001T is a novel immune checkpoint target discovered by Compugen using its proprietary computational discovery platform. It is part of a broader effort to identify new pathways that regulate T-cell activity within the tumor microenvironment, similar to the PVRIG and TIGIT pathways. The target is believed to play a significant role in suppressing the immune system's ability to recognize and destroy cancer cells. By targeting CGEN-15001T, researchers aim to restore the anti-tumor activity of T-cells and improve outcomes for patients with various solid tumors. Compugen has developed CGEN-15001, an Fc-fusion protein based on this target, which has shown potential in preclinical models for both oncology and autoimmune applications by modulating immune homeostasis.

Other names

CGEN-15001Compugen-15001T

CGEN-15001T is a novel immune checkpoint target discovered by Compugen. Therapeutic strategies involve using CGEN-15001 (an Fc-fusion protein of the target) to modulate immune responses or developing antibodies to block the receptor's immunosuppressive activity in the tumor microenvironment.